Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alzheimer disease (AD) is a major threat of twenty-first century that is responsible for the majority of dementia in the elderly. Development of effective AD-preventing therapies are the top priority tasks for neuroscience research. Amyloid hypothesis of AD is a dominant idea in the field, but so far all amyloid-targeting therapies have failed in clinical trials. In addition to amyloid accumulation, there are consistent reports of abnormal calcium signaling in AD neurons. AD neurons exhibit enhanced intracellular calcium (Ca(2) (+)) liberation from the endoplasmic reticulum (ER) and reduced store-operated Ca(2) (+) entry (SOC). These changes occur primarily as a result of ER Ca(2) (+) overload. We argue that normalization of intracellular Ca(2) (+) homeostasis could be a strategy for development of effective disease-modifying therapies. The current review summarizes recent data about changes in ER Ca(2) (+) signaling in AD. Ca(2) (+) channels that are discussed in the current review include: inositol trisphosphate receptors, ryanodine receptors, presenilins as ER Ca(2) (+) leak channels, and neuronal SOC channels. We discuss how function of these channels is altered in AD and how important are resulting Ca(2) (+) signaling changes for AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · cited 2×
“One of the main therapeutic approaches to AD is focused on development of γ-secretase inhibitors (GSIs) and modulators, however so far this approach has failed in phase III clinical trials of Eli–Lilly’s Semagacestat, a non-selective GSI (Doody et al., 2013).”
BackgroundAph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 1×
“PS1 and PS2 constitute the catalytic pore of the γ-secretase complex, other partner of the complex are nicastrin, aph-1, and pen-2 (De Strooper, 2003).”
BackgroundNeuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938
(2014) · doi:10.1523/jneurosci · Cited by 715
Kuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H.-Y., Hyman, B. T., & Bacskai, B. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.008 · Cited by 614
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 2×
“Aβ40, Aβ42, and NFT are synaptotoxic to neurons and facilitate cell death (Small and Duff, 2008).”
BackgroundInfluentialDeleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468
Howlett, D. R., Richardson, J. C., Austin, A., Parsons, A. A., Bate, S. T., Davies, D. C., & Gonzalez, M. I. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.029 · Cited by 212
Chakroborty, S., Kim, J., Schneider, C., Jacobson, C., Molgo, J., & Stutzmann, G. E. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0936-12.2012 · Cited by 118
Cited by
Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives
Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., Pramodh, S., Alsulimani, A., Alkhanani, M. F., Harakeh, S., et al. (2022) · Cells · doi:10.3390/cells11030552 · Cited by 915
Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537
Sun, S., Zhang, H., Liu, J., Popugaeva, E., Xu, N.-J., Feske, S., White, C. L., & Bezprozvanny, I. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.019 · Cited by 272
Self-citationLacampagne, A., Liu, X., Reiken, S., Bussiere, R., Meli, A. C., Lauritzen, I., Teich, A. F., Zalk, R., Saint, N., Arancio, O., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1733-7 · Cited by 181
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Metadata
- Authors
- Popugaeva, E., & Bezprozvanny, I.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 6
- Pages
- 29-29
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2099249066
- Cited by
- 106
- References
- 10
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.